Get the Stockscreener App
42.78
2.92%
1.215
After Hours:
42.77
-0.015
-0.04%
Exelixis Inc stock is traded at $42.78, with a volume of 1.83M.
It is up +2.92% in the last 24 hours and down -4.39% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$41.57
Open:
$42
24h Volume:
1.83M
Relative Volume:
0.66
Market Cap:
$11.11B
Revenue:
$2.32B
Net Income/Loss:
$782.57M
P/E Ratio:
15.37
EPS:
2.7838
Net Cash Flow:
$875.84M
1W Performance:
+3.70%
1M Performance:
-4.39%
6M Performance:
+10.58%
1Y Performance:
+13.46%
1-Day Range:
$41.87
$43.48
1-Week Range:
$40.84
$43.48
52-Week Range:
$32.38
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL vs VRTX, REGN, ALNY, ARGX, INSM
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
42.78 | 10.80B | 2.32B | 782.57M | 875.84M | 2.7838 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 113.96B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 78.41B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 40.85B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 42.05B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 29.99B | 606.42M | -1.28B | -997.58M | -6.403 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-08-26 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-26 | Downgrade | BofA Securities | Neutral → Underperform |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
EXEL: Former Executive Joins Recursion Pharmaceuticals as New CM - GuruFocus
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
EXEL Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Quarterly Trades: Will Exelixis Inc outperform its industry peersMarket Volume Report & Capital Protection Trade Alerts - baoquankhu1.vn
Private Client Services LLC Takes $1.99 Million Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong value stock - MSN
Strategic Investment Advisors MI Buys 27,659 Shares of Exelixis, Inc. $EXEL - MarketBeat
How Exelixis Inc. (EXEL) Affects Rotational Strategy Timing - Stock Traders Daily
Pharma Stocks Analysis 2026: Pfizer & Novo Nordisk Rebound, Exelixis GrowthNews and Statistics - IndexBox
Here's Why Exelixis (EXEL) is a Strong Value Stock - Yahoo Finance
The Best Healthcare Stocks to Buy With $50 Right Now - The Motley Fool
Portfolio Update: What is the earnings history of Exelixis Inc2026 Highlights & AI Powered Trade Plan Recommendations - baoquankhu1.vn
L2 Asset Management LLC Invests $3.36 Million in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (EXEL) Valuation After Earnings Beat FDA Progress And Cabometyx Label Expansion - Yahoo Finance
Exelixis, Inc. $EXEL Shares Acquired by Clark Capital Management Group Inc. - MarketBeat
Exelixis Highlights Zanzalintinib RCC Trials, Sequencing Debate, and December CRC PDUFA at Leerink - MarketBeat
Exelixis Highlights CABOMETYX Growth, Zanzalintinib PDUFA and Pipeline Strategy at Barclays Conference - MarketBeat
Exelixis Highlights $2.4B 2026 Outlook, Cabometyx Momentum and Zanzalintinib Catalysts at Conference - MarketBeat
Exelixis Inc Stock (ISIN: US30161Q1040) Gains Momentum on Earnings Beat and Zanzalintinib FDA Milest - AD HOC NEWS
Capital Impact Advisors LLC Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
How Exelixis’ Earnings Beat and FDA Zanzalintinib Milestone Will Impact Exelixis (EXEL) Investors - simplywall.st
Exelixis, Inc. $EXEL Stake Raised by South Street Advisors LLC - MarketBeat
Exelixis (NASDAQ:EXEL) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat
EXEL SEC FilingsExelixis Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Assessing Exelixis (EXEL) Valuation After Analysts Lift 2026 Earnings Forecasts - simplywall.st
Schroder Investment Management Group Has $22.95 Million Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Here's why Exelixis (EXEL) is a strong growth stock - MSN
Exelixis (EXEL) Down 2.8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Here’s What Makes Exelixis (EXEL) a Top Growth Stock - Bitget
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Exelixis at Barclays Healthcare: Strategic Growth and Pipeline Insights By Investing.com - Investing.com Canada
EXEL: Zanzalintinib and CABOMETYX anchor growth in GI/GU oncology, with robust pipeline momentum - TradingView
EXEL: Zanza and new indications drive growth, targeting $2.4B revenue and leadership in key oncology markets - TradingView
First Trust Advisors LP Has $59.35 Million Holdings in Exelixis, Inc. $EXEL - MarketBeat
Barclays PLC Boosts Stock Holdings in Exelixis, Inc. $EXEL - MarketBeat
Exelixis at Leerink Global Healthcare Conference: Strategic Insights in RCC and CRC - Investing.com Canada
Exelixis Q4 2025 slides: Strong earnings growth amid oncology franchise expansion - Investing.com Nigeria
Dimensional Fund Advisors LP Grows Holdings in Exelixis, Inc. $EXEL - MarketBeat
Victory Capital Management Inc. Acquires 187,034 Shares of Exelixis, Inc. $EXEL - MarketBeat
What is Zacks Research's Estimate for Exelixis Q3 Earnings? - MarketBeat
Crossmark Global Holdings Inc. Boosts Stock Position in Exelixis, Inc. $EXEL - MarketBeat
Exelixis, Inc. Experiences Revision in Stock Evaluation Amid Market Dynamics - Markets Mojo
(EXEL) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Teton Advisors LLC Makes New Investment in Exelixis, Inc. $EXEL - MarketBeat
Exelixis (NASDAQ:EXEL) Cut to Hold at Zacks Research - MarketBeat
Gainers Report: Will Exelixis Inc benefit from rising consumer demandWeekly Trend Summary & Smart Investment Allocation Tips - baoquankhu1.vn
Exelixis, Inc. (NASDAQ:EXEL) Given Average Recommendation of "Hold" by Analysts - MarketBeat
American Century Companies Inc. Raises Position in Exelixis, Inc. $EXEL - MarketBeat
Elo Mutual Pension Insurance Co Buys 30,279 Shares of Exelixis, Inc. $EXEL - MarketBeat
A Look At Exelixis (EXEL) Valuation As Analyst Optimism Builds Around Its Oncology Pipeline - simplywall.st
EXEL: Zanzalintinib advances toward launch as pivotal trials and franchise expansion drive future growth - TradingView
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):